Grassley probes insurer over 'penalties' for brand-name drugs
Grassley probes insurer over 'penalties' charged for brand ... Grassley has expressed concern that some people may instead feel they have no choice but to opt for lower-cost generic drugs that, in such situations, may not be as effective. "The issues at stake not only have a financial impact, but a medical impact," Grassley wrote in a letter to CareFirst CEO Chet Burrell on Monday. Grassley probes insurer over 'penalties' for brand-name drugs There is no point is responding to Mr. Nakajima. He obviously has not studied the issue – I spent over a year doing so, including FDA explanations for why it was compelled to pull generic versions of Wellbutrin off the market – and well as multiple court decisions addressed to issues patients have with generic drugs, and brand penalties.
Grassley Probes Insurer Over Penalties For Brand Name Drugs is one of our best images of interior design living room furniture and its resolution is 645x645 pixels. Find out our other images similar to this Grassley Probes Insurer Over Penalties For Brand Name Drugs at gallery below.
Below are the images from